1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
P3: Pandemic Prevention Platform is sponsored by Defense Advanced Research Projects Agency (DARPA). The P3 program aims to support military readiness and global stability by pursuing novel methods to dramatically accelerate the discovery, integration, pre-clinical testing, and manufacturing of medical countermeasures against infectious diseases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Pandemic Prevention Platform (P3) Department of War organization. P3: Pandemic Prevention Platform P3: Pandemic Prevention Platform The Pandemic Prevention Platform (P3) program aims to support military readiness and global stability through pursuit of novel methods to dramatically accelerate discovery, integration, pre-clinical testing, and manufacturing of medical countermeasures against infectious diseases.
P3 confronts the reality that Department of Defense (DoD) personnel are not only deployed around the world for routine operations, but are often among the first responders to outbreaks of emerging or re-emerging disease with pandemic potential (e.g., Ebola).
P3 aims specifically to develop a scalable, adaptable, rapid response platform capable of producing relevant numbers of doses against any known or previously unknown infectious threat within 60 days of identification of such a threat in order to keep the outbreak from escalating and decrease disruptions to the military and homeland.
State-of-the-art medical countermeasures often take many months or even years to develop, produce, distribute, and administer. The envisioned P3 platform would cut response time to weeks and stay within the window of relevance for containing an outbreak.
P3 focuses on rapid discovery, characterization, production, testing, and delivery of efficacious DNA- and RNA-encoded medical countermeasures, a foundational technology pioneered by DARPA under the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program that provides the body with instructions on how to immediately begin producing protective antibodies against a given threat.
The P3 program seeks to unlock the potential of these coded genetic constructs—establishing them as the basis for a threat-agnostic platform technology—by achieving and integrating breakthroughs in three key areas: Novel approaches for the growth of viruses for use in testing and evaluation of countermeasures Rapid identification and maturation of protective antibodies to increase their potency Novel technologies for the delivery of nucleic acid constructs into patients to encode the antibody of interest and produce a protective response.
A principal benefit of the nucleic-acid-based approach to limiting the spread of infection is that genetic constructs introduced into the body would process quickly and not integrate into an individual’s genome. Similarly, the antibodies produced in response to treatment would only be present in the body for weeks to months.
This is consistent with DARPA's intent to safely deliver transient immunity, halting the spread of disease by creating a firewall, and buying time for longer-term medical responses to be developed and deployed. Biological Technologies Office This program is now complete. This content is available for reference purposes.
This page is no longer maintained.
According to the current listing, eligibility includes: Researchers and organizations capable of developing novel approaches for the growth of viruses, rapid identification and maturation of protective antibodies, and novel technologies for the delivery of nucleic acid const…. Confirm the full requirements in the official notice before applying.
P3: Pandemic Prevention Platform is funded by Defense Advanced Research Projects Agency (DARPA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
DPA26BZ06-DV023 is a Direct-to-Phase-II SBIR paying $700,000 over 18 months plus a $500,000 option. The physics demands 256x more transmit power than the systems that qualify you to compete, and DARPA will not accept modeling alone as proof. Here is the eligibility wall, the five engineering problems, and who can realistically win it before the October 21 close.
Read articleRelease 6's SBIR topics got the attention. Its three STTR topics — SHIELDER, fuel-flexible electric propulsion, and hypersonic wind tunnel noise diagnostics — are all Direct-to-Phase-II, all require a research institution to perform at least 30 percent of the work, and all close October 21, 2026. The feasibility gates are the real filter.
Read articleDPA26BZ06-DV026 offers $300,000 at Phase I or $1,800,000 as a single Direct-to-Phase-II tranche with no options. The deliverable is a simulated auction market that measures whether AI agents deceive, collude, or manipulate the humans they serve — measured entirely from the outside. Here is the 90% efficiency gate, the team composition most bidders will get wrong, and why this topic sits in DARPA's biology office.
Read article